Spravato is presently approved in combination ... estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

The FDA approved esketamine (Spravato) nasal spray as monotherapy ... differences of -5.1 with the 56-mg dose and -6.8 with ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...

The analyst identified the finding as eliminating “the need for frequent re-dosing seen with JNJ's Spravato." He argued that the commercial success of JNJ's ketamine-based therapy could support ...

My practice is integrated care for adults (psychiatric medication management, psychedelic esketamine (Spravato) treatments, primary care, weight loss injection therapy and asthetics). I am board ...